NGM to chart new course for lead compound
NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) said its NGM282 met the primary endpoint in a Phase II trial to treat primary biliary cirrhosis (PBC), but now plans to study the compound to treat other Orphan bile acid-related diseases. The company said PBC patients may have treatment alternatives before NGM282...
Read the full 240 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$35 USD
